18:43 , Sep 7, 2018 |  BC Week In Review  |  Clinical News

EyeGate weighing options for EGP-437 after uveitis failure

EyeGate Pharmaceuticals Inc. (NASDAQ:EYEG) said EGP-437 did not show non-inferiority to prednisolone opthalmic solution in a Phase III trial to treat non-infectious anterior segment uveitis. The company is assessing strategic options for the product, which...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
18:46 , Feb 9, 2018 |  BC Week In Review  |  Clinical News

EyeGate's ocular pain and inflammation candidate misses in Phase IIb

EyeGate Pharmaceuticals Inc. (NASDAQ:EYEG) reported top-line data from a double-blind, U.S. Phase IIb trial to treat post-operative ocular pain and inflammation in 106 patients who had previously undergone cataract surgery with implantation of a monofocal...
19:00 , Feb 24, 2017 |  BC Week In Review  |  Company News

Eyegate, Valeant deal

EyeGate granted Valeant exclusive, worldwide rights to manufacture and commercialize EGP-437 in combination with the EyeGate II Drug Delivery System to treat postoperative pain and inflammation in ocular surgery patients. The dexamethasone phosphate ophthalmic solution...
00:53 , Dec 31, 2016 |  BioCentury  |  Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are...
07:00 , Aug 15, 2016 |  BC Week In Review  |  Clinical News

EGP-437: Phase Ib/IIa data

Top-line data from 40 patients who had previously undergone cataract surgery with the implantation of a posterior chamber intraocular lens in an open-label Phase Ib/IIa trial showed that 14 mA-min EGP-437 on days 0, 1...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Clinical News

EGP-437: Phase III started

EyeGate began a double-blind, placebo-controlled, U.S. Phase III trial to evaluate 3 treatments of 40 mg/mL EGP-437 delivered iontophoretically in up to 250 patients. The EGP-437 arm will receive placebo eye drops and the placebo...
07:00 , Aug 17, 2015 |  BC Week In Review  |  Company News

EyeGate, Valeant Pharmaceuticals deal

EyeGate granted Valeant exclusive rights to develop and commercialize EGP-437 in combination with EyeGate II Drug Delivery System for anterior uveitis. EyeGate will receive $1 million upfront, and is eligible to receive up to $32.5...
07:00 , Jul 20, 2015 |  BC Week In Review  |  Clinical News

EGP-437: Phase Ib/IIa started

EyeGate began an open-label, U.S. Phase Ib/IIa trial to evaluate 40 mg/mL EGP-437 on days 0, 4 and 14 in up to 20 patients with retinal vein occlusion (RVO), diabetic macular edema (DME) or postsurgical...
02:56 , Nov 21, 2014 |  BC Extra  |  Financial News

EyeGate downsizes proposed IPO

Ophthalmology company EyeGate Pharmaceuticals Inc. (Waltham, Mass.) amended terms for its proposed IPO on NASDAQ underwritten by Aegis Capital Corp. The company now plans to sell 1.4 million shares at $6-$8. At $7, EyeGate would...